C4 Therapeutics, Inc. CCCC
3.00 USD -0.15 (-4.76%)
At closeNov 10, 2026, 7:59 PM EST
3.05 +0.05 +1.63%
After hours · Nov 10, 7:59 PM ET
2.93 Day range 3.16
1.69 52-week range 5.17
- YTD
- +57.07%
- 1 year
- +28.21%
News
benzinga.com Guggenheim Maintains Buy on C4 Therapeutics, Lowers Price Target to $6 Guggenheim analyst Michael Schmidt maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and lowers the price target from $7 to $6.
zacks.com C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.44 per share a year ago.
benzinga.com C4 Therapeutics Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $8.468M Miss $8.514M Estimate C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 63.64 percent increase over losses of…
globenewswire.com C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide…
globenewswire.com C4 Therapeutics to Participate in Upcoming November Investor Conferences WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…
globenewswire.com C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,…
zacks.com C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release C4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…
benzinga.com Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11 Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
defenseworld.net Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the…
prnewswire.com Insmed Appoints Two New Directors to Its Board —Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J.,…
defenseworld.net Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC) C4 Therapeutics (NASDAQ: CCCC - Get Free Report) and ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the…
benzinga.com JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10 JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.- benzinga.com C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of ActionBiomarker Data from First…
globenewswire.com C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action
zacks.com Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
benzinga.com C4 Therapeutics To Present New Biomarker Data On Immunomodulatory Effects Of Cemsidomide In Combination With Dexamethasone From Phase 1 Trial For RRMM At IMS Annual Meeting C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the…
globenewswire.com C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…
defenseworld.net Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS) Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
zacks.com Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.37 per share a year ago.
benzinga.com C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of…
zacks.com Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
zacks.com C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings…
seekingalpha.com C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
zacks.com Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.- benzinga.com C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was…
globenewswire.com C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status- benzinga.com Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12 Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
benzinga.com Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results US stocks mixed, Nasdaq up 200 points. Dow down 0.43%, Nasdaq up 0.79%, S&P 500 up 0.27%. Communication services up 1.6%, utilities down 1.4%. Alibaba shares up 6% after reporting mixed Q4 results.…
benzinga.com Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeutics (CCCC) up 19.4%, Kingsoft Cloud (KC) up 18.6%, Tower Semiconductor (TSEM) up 17.5%, Nebius…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 45.95 percent increase over losses of…
benzinga.com C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.- benzinga.com C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new…
benzinga.com C4 Therapeutics Starts Trial For New Multiple Myeloma Drug Combo C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been…
benzinga.com Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7 Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $7.
benzinga.com Earnings Summary: C4 Therapeutics Q4 - benzinga.com C4 Therapeutics Q4 EPS $(0.18) Beats $(0.31) Estimate, Sales $11.016M Beat $6.460M Estimate C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 41.37 percent. This is a 63.27 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30 Brookline Capital analyst Leah Rush maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $20 to $30.
- benzinga.com C4 Therapeutics Doses First Patient In Phase 2 MOMENTUM Trial Of Oral Cemsidomide With Dexamethasone For Relapsed Refractory Multiple Myeloma Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026
- benzinga.com C4 Therapeutics Positions Cemsidomide As Potential Best-In-Class Myeloma Therapy While Expanding Discovery Efforts Beyond Oncology Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µgCemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2…
- benzinga.com Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5 Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.
benzinga.com This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday 
benzinga.com This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - benzinga.com C4 Therapeutics Q3 EPS $(0.44) Misses $(0.40) Estimate, Sales $11.230M Beat $6.280M Estimate C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40) by 10.28 percent. This is a 25.71 percent decrease over losses of…